ClinicalTrials.gg
Active, not recruitingNCT04379596DG-03Updated Aug 28, 2026

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

A Phase 2 interventional study of Fluorouracil (5-FU) and Capecitabine in Gastric Cancer, sponsored by AstraZeneca. Active, not recruiting at 71 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms — 9 open to participants now, 11 under way, 3 of them phase 3. trastuzumab deruxtecan · Stomach Neoplasms.

Enrollment
4th of 14
452 · median 78
Started
2020
the only one that year
Phase 2
6 of 14
4 open now
Primary completion
2027-05
later than 5 of 10 live
Registered
2nd of 14
by date
Lead sponsor
4 of 14
AstraZeneca

Among the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 2nd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, or all of them as a file.
02

Study summary

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients.

Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-expressing gastric, GEJ and esophageal cancer patients who have not received prior treatment for advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the potential to become a therapeutic option for this patient population.

03

Conditions studied

  • Gastric Cancer

Keywords

  • Gastric Cancer
  • Esophageal Cancer
  • Carcinoma
  • HER2
  • Trastuzumab
  • Deruxtecan
  • T-DXd
  • DS-8201a
  • Gastroesophageal Cancer
  • Adenocarcinoma
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be at least 18 years of age. Other age restrictions may apply as per local regulations
  2. Disease Characteristics:

    1. Locally advanced, unresectable, or disease based on most recent imaging
    2. For Part 1, 2, 3a, 4a documented adenocarcinoma of the stomach/GEJ/esophagus, -positive (IHC 3+ or IHC 2+/ISH+) based on local tissue testing results
    3. For Part 3b,4b and Part 5, pathologically documented adenocarcinoma of the stomach/GEJ/esophagus, HER2-low (IHC 2+/ISH-negative or IHC 1+) based on local tissue testing results
  3. For Part 1, progression on or after at least one prior trastuzumabcontaining regimen For Part 2, Part 3, Part 4 and Part 5, previously untreated for unresectable or metastatic adenocarcinoma of the stomach/GEJ/ esophagus with with HER2-positive (Part 2 and Part 3 [Arm 3A] and Part 4 [Arm 4A]) or HER2-low (Part 3 [Arm 3B], Part 4 [Arm 4B] and Part 5)) status
  4. Has measurable target disease assessed by the Investigator based on version 1.1
  5. Has protocol defined adequate bone marrow and organ function including cardiac, renal and hepatic function
  6. If of , agrees to use a highly effective form of or avoid intercourse during and upon completion of the study.

Exclusion criteria

Exclusion criteria:

  1. Part 1 to 4: History of active primary immunodeficiency, known , active chronic, or past infection, or infection. Part 5: evidence of active, uncontroled HIV, HBV or HCV infection.
  2. Uncontrolled intercurrent illness.
  3. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening.
  4. Lung-specific intercurrent severe illnesses.
  5. Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  6. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).
  7. Has spinal cord compression or clinically active central nervous system .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Arm 1A

    T-DXd and 5-fluorouracil (5-FU)

    Drug: Fluorouracil (5-FU) · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 1B

    T-DXd and capecitabine

    Drug: Capecitabine · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 1C

    T-DXd and durvalumab

    Biological: Durvalumab · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 1D(b)

    T-DXd, capecitabine, and oxaliplatin

    Drug: Capecitabine · Drug: Oxaliplatin · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 1E(a)

    T-DXd, 5-FU, and durvalumab

    Drug: Fluorouracil (5-FU) · Biological: Durvalumab · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 1E(b)

    T-DXd, capecitabine, and durvalumab

    Drug: Capecitabine · Biological: Durvalumab · Drug: Trastuzumab deruxtecan

  • Active comparator
    Arm 2A

    Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Oxaliplatin · Biological: Trastuzumab · Drug: Cisplatin

  • Experimental
    Arm 2B

    T-DXd monotherapy

    Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 2C

    T-DXd, 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 2D

    T-DXd, pembrolizumab and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab

  • Experimental
    Arm 2E

    T-DXd and pembrolizumab

    Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab

  • Experimental
    Arm 2F

    T-DXd, pembrolizumab and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab

  • Experimental
    Arm 3A

    T-DXd, Volrustomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig

  • Experimental
    Arm 3B

    T-DXd, Volrustomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig

  • Experimental
    Arm 4A

    T-DXd, Rilvegostomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Rilvegostomig

  • Experimental
    Arm 4B

    T-DXd, Rilvegostomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Rilvegostomig

  • Experimental
    Part 5 Main Cohort

    T-DXd, Volrustomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig

  • Experimental
    Part 5 Cohort 2

    T-DXd, Volrustomig and 5-FU or capecitabine

    Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig

Interventions

  • 5-FU: administered as an IV infusion

  • Capecitabine: administered orally

  • BiologicalDurvalumab

    Durvalumab: administered as an IV infusion

    Also known as: MEDI4736

  • Oxaliplatin: administered as an IV infusion

  • BiologicalTrastuzumab

    Trastuzumab: administered as an IV infusion

  • T-DXd: administered as an IV infusion

    Also known as: DS-8201a, Enhertu

  • Cisplatin: administered as an IV infusion

  • BiologicalPembrolizumab

    Pembrolizumab: administered as an IV infusion

  • BiologicalVolrustomig

    Volrustomig: administered as an IV infusion

    Also known as: MEDI5752

  • BiologicalRilvegostomig

    Rilvegostomig: administered as an IV infusion

    Also known as: AZD2936

06

What researchers measure

Primary outcomes

  1. Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0

    Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0

    Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.

  2. Part 1: Ocurrence of dose-limiting toxicities (DLTs)

    Occurrence of dose limiting toxicities

    Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.

  3. Part 1: Changes from baseline in laboratory parameters

    Changes in laboratory parameters (every in appropriate units) compared to baseline results.

    Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.

  4. Part 1: Changes from baseline in vital signs

    Changes in vital signs results compared to baseline results.

    Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.

  5. Part 1: Changes from baseline in electrocardiogram (ECG) results

    Changes in ECG results compared to baseline results.

    Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.

  6. Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)

    Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.

    Time frame: (Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months

Secondary outcomes

  1. Part 1: Objective Response Rate (ORR)

    Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.

    Time frame: Efficacy will be assessed at an average of approximately 12 months

  2. Part 2, Part 3, Part 4 and Part 5: Occurrence of adverse events (AEs) and serious adverse events (SAEs)

    Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0

    Time frame: Safety will be assessed up to follow-up period, approximately 24 months

  3. Part 2, Part 3, Part 4 and Part 5: Changes from baseline in laboratory parameters

    Changes in laboratory parameters (every in appropriate units) compared to baseline results.

    Time frame: Safety will be assessed up to follow-up period, approximately 24 months

  4. Part 2, Part 3, Part 4 and Part 5: Changes from baseline in vital signs

    Changes in vital signs results compared to baseline results.

    Time frame: Safety will be assessed up to follow-up period, approximately 24 months

  5. Part 2, Part 3 , Part 4 and Part 5: Changes from baseline in body weight

    Changes in body weight in kilograms compared to baseline results.

    Time frame: Safety will be assessed up to follow-up period, approximately 24 months

  6. Part 2, Part 3, Part 4 and Part 5: Changes from baseline in electrocardiogram (ECG) results

    Changes in ECG results compared to baseline results.

    Time frame: Safety will be assessed up to follow-up period, approximately 24 months

  7. Duration of Response (DoR)

    DOR is defined as the time from the date of first documented response until the date of documented progression or death

    Time frame: Until progression or death, efficacy (DoR) will be assessed up to approximately 24 months

  8. Disease Control Rate (DCR)

    DCR is the percentage of subjects who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD)

    Time frame: Efficacy will be assessed at an average of approximately 12 months

  9. Progression Free Survival (PFS)

    PFS is the time from date of first dose until the date of objective disease progression or death

    Time frame: Until progression or death, efficacy (PFS) will be assessed up to approximately 24 months

  10. Overall survival (OS)

    OS is the time from date of first dose until death due to any cause

    Time frame: Until death, efficacy (OS) will be assessed up to approximately 24 months

  11. Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181a in all arms

    Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for each dose level for T-DXd, total anti-HER2 antibody, MAAA-1181a

    Time frame: While on study drug up to study completion, approximately 24 months

  12. Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab

    Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab.

    Time frame: While on study drug up to study completion, approximately 24 months

  13. Presence of ADAs for T-DXD, durvalumab, volrustomig and rilvegostomig (in study arms including T-DXd and durvalumab, and T-DXd and volrustomig, and T-DXd and rilvegostomig respectively)

    Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd and durvalumab.

    Time frame: While on study drug up to study completion, approximately 24 months

  14. Serum concentrations of volrustomig and rilvegostomig in study arms including T-DXd in combination with volrustomig and T-DXd in combination with rilvegostomig

    Individual participant data and descriptive statistics will be provided for data at each time point for rilvegostomig and volrustomig

    Time frame: While on study drug up to study completion, approximately 24 months

  15. Comparison of ORR

    Comparison of objective response rate between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results

    Time frame: While on study drug up to study completion, approximately 24 months

  16. Comparison of DCR

    Comparison of disease control rate between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results

    Time frame: While on study drug up to study completion, approximately 24 months

  17. Comparison of DoR

    Comparison of duration of response between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results

    Time frame: While on study drug up to study completion, approximately 24 months

  18. Comparison of PFS

    Comparison of progression-free survival between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results

    Time frame: While on study drug up to study completion, approximately 24 months

  19. Comparison of OS

    Comparison of overall survival between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results

    Time frame: While on study drug up to study completion, approximately 24 months

07

Study locations

71 sites
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São Jose Do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 045202-001, Brazil
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    Hamburg, 20249, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Amsterdam, 1066CX, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Utrecht, 3584CG, Netherlands
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Konin, 62-500, Poland
  • Research Site
    Koszalin, 75-581, Poland
  • Research Site
    Krakow, 31-501, Poland
  • Research Site
    Warsaw, 02-034, Poland
  • Research Site
    Kostroma, 156005, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 125284, Russia
  • Research Site
    Moscow, 143423, Russia
  • Research Site
    Moscow, 143442, Russia
  • Research Site
    Novosibirsk, 630099, Russia
  • Research Site
    Saint Petersburg, 195271, Russia
  • Research Site
    Saint Petersburg, 196603, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    London, NW1 2PG, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Publications

  • Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Informed consent form

Time frame: Study start to completion date

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for May 2027, 83 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 83 months is above that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2020
First posted
May 7, 2020
StartActual
Jun 3, 2020
Primary completionEst.
May 4, 2027
CompletionEst.
May 4, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04379596
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 7, 2020
Start date
Jun 3, 2020
Primary completion
May 4, 2027 (estimated)
Completion
May 4, 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Volrustomig · Rilvegostomig

Start the discussion